Educational Symposiums

  • S6 : EDUCATIONAL SYMPOSIUM: EVALUATIONS ON THE HEALTH TECHNOLOGY ASSESSMENT ERA IN JAPAN – FROM GOVERNMENTAL, ACADEMIC, AND PHARMACEUTICAL PERSPECTIVES

    Presentation

    Ataru Igarashi
    PhD , Associate Professor, University of Tokyo, Department of Drug Policy and Management, Tokyo, Japan
  • S7 : EDUCATIONAL SYMPOSIUM: VALUE-BASED DECISION MAKING IN DEVELOPING COUNTRIES: MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR OFF-PATENT PHARMACEUTICALS

    Presentation

    Anke-Peggy Holtorf
    PhD, MBA , Managing Director, GmbH, Health Outcomes Strategies, Basel, Switzerland
    Kalman Emry Wijaya
    PharmD., MBA , Global Market Access and Policy Sr. Manager, Abbott Products Operations AG, Global Market Access, Allschwil, Switzerland
    Diana Brixner
    PhD, RPh, FAMCP , Professor, Department of Pharmacotherapy, University of Utah College of Pharmacy,, University of Utah,, Executive Director, Pharmacotherapy Outcomes Research Center, and Director of Outcomes,, Salt Lake City,, USA
    Zoltan Kalo
    PhD , Professor of Health Economics, Eötvös Loránd University (ELTE), 2) Syreon Research Institute, Budapest, Hungary
    Nikos Maniadakis,
    Professor , Director, Alternate Dean, National School of Public Health,, Department of Health Services Organization & Management, Athens, Greece
  • S8 : EDUCATIONAL SYMPOSIUM: CHALLENGES AND OPPORTUNITIES IN VALUE ASSESSMENT OF INNOVATIVE BIOLOGIC MEDICINES

    Presentation

    Presentation

    Marty Jovic,
    MS , Partner, PricewaterhouseCoopers Consulting (Australia) Pty Limited, Barangaroo, Australia
    Jinxi Ding
    PhD, Professor and Vice Dean, , China Pharmaceutical University, School of International Pharmaceutical Business, , Nanjing, China

PLENARY SESSIONS

  • PL1 : Transforming Healthcare and Leveraging Digital Health for Better Health in Asia-Pacific

    Presentation

    Presentation

    Presentation

    Erwin Loh
    MBBS, LLB(Hons), MBA, MHSM, PhD , Executive Director, Chief Medical Officer, Monash Health, Innovation, Patient Safety & Experience, Melbourne, Australia
    Gabe Rijpma
    Senior Director, Microsoft Asia, Health and Social Services, Auckland, New Zealand
    Polawat Witoolkollachit
    MD, Director, Ministry of Public Health (MOPH), Information Technology and Communication, Bangkok, Thailand
    Lou Huei-Xin
    PharmD, MSc (Clinical Pharm) , Director, Ancillary Care, Integrated Health Information Systems Pte Ltd, Head, National Pharmacy Program Management Office, Ministry of Health, Singapore, Singapore
  • PL2 : Real World Evidence in Asia-Pacific: Are We Ready? Is It Helpful for Decision Makers?

    Presentation

    Presentation

    Presentation

    Bart Barefoot
    Director & VEO , GlaxoSmithKline, Real World Evidence Policy and Advocacy, Value Evidence and Outcomes (VEO), Global Medical, London, UK
    Kinwei Arnold Chan
    MD, ScD, FISPE , Director, Health Data Research Center, National Taiwan University, National Taiwan University Hospital, Department of Medical Research, and Director, Clinical Trial Center, Taipei, Taiwan
    Manabu Akazawa
    PhD, MPH , Professor, Meiji Pharmaceutical University, Public Health and Epidemiology Department, Tokyo, Japan
    Xin Sun
    PhD , Professor & Director, Sichuan University, Chinese Evidence-Based Medicine Center, West China Hospital, Chengdu, China
  • PL3 : Risk Sharing Agreements: Country Experiences, Challenges, and Lessons Learned

    Presentation

    Presentation

    Presentation

    Jang Sae Rak
    Deputy Director, Health Insurance Review and Assessment Service, Pharmaceutical Listing Division, Pharmaceutical Benefit Department, Seoul, South Korea
    Jörg Mahlich
    PhD, Head, Health Economics and Outcomes Research, Janssen Pharmaceutical, Formal Director, Health Economics in Janssen Japan, Neuss, Germany
    Elizabeth de Somer
    Director, Medicines Australia, Policy & Research and Interim Chief Executive Officer, Canberra, Australia
    Gergana Zlateva
    PhD, Vice President, Pfizer Inc., Global Market Access-Oncology, Global Health & Value, New York, USA

ISSUE PANEL PRESENTATIONS

  • IP1 : COST VS VALUE: WHAT IS THE FAIR PRICE OF A DRUG?

    Presentation

    Presentation

    Presentation

    Mark Sculpher
    PhD, University of York, Centre for Health Economics, York, United Kingdom
    Takashi Fukuda
    PhD, National Institute of Public Health, Wako, Japan
    Christoph Glaetzer
    Dipl. Kfm, Janssen, Pharmaceutical Companies of Johnson&Johnson, NJ, USA
  • IP10 : WHAT EVIDENCE SHOULD BE USED TO QUANTIFY COST-EFFECTIVENESS THRESHOLDS FOR DECISION-MAKING IN THE ASIA PACIFIC REGION?

    Presentation

    Presentation

    Presentation

    Mark Sculpher
    PhD, University of York, Centre for Health Economics, York, United Kingdom
    Yot Teerawattananon
    PhD, Health Intervention and Technology Assessment Program (HITAP), Muang, Nonthaburi, Thailand
    Jonathan Karnon
    PhD, The University of Adelaide, School of Public Health, Adelaide, Australia
  • IP11 : A TRIAL HTA INTRODUCTION IN JAPAN: LEARNING AND WAY FORWARD

    Presentation

    Takashi Fukuda
    PhD, National Institute of Public Health, Department of Health and Welfare Services, Wako, Japan
  • IP12 : HOW TO MEASURE AND VALUE HEALTH BENEFITS TO FACILITATE PRIORITY SETTING FOR PEDIATRIC POPULATION? DEVELOPMENT AND APPLICATION ISSUES

    Presentation

    Presentation

    Presentation

    Gang Chen
    PhD, MSc, BMed, Monash University, Centre for Health Economics, Monash Business School, Melbourne, Australia
    Nan Luo
    PhD, National University of Singapore, Saw Swee Hock School of Public Health, Singapore, Singapore
    Ruoyan Gai
    PhD, National Center for Child Health and Development of Japan, Division of Policy Evaluation, Department of Health Policy and Chief, Division of Health Technology Assessment, Department of Clinical Epidemiology, Tokyo, Japan
  • IP13 : MCDA IN HTA: WOULD MCDA BE A VALUABLE ADDITION TO THE CURRENT JAPANESE HTA SYSTEM?

    Presentation

    Presentation

    Presentation

    Yot Teerawattananon
    Dr., HUTAP, Department of Health, Ministry of Public Health, Nonthaburi, Thailand
    Ataru Igarashi
    PhD, University of Tokyo, Department of Drug Policy and Management, Tokyo, Japan
    Omer Saka
    MD, MSc, Deloitte Belgium, Health Economics and Outcomes Research, Zaventem, Belgium
  • IP14 : MANAGED ENTRY SCHEMES: HYPE VS. REALITY

    Presentation

    Presentation

    Presentation

    Jeonghoon Ahn
    PhD, Ewha Womans University, Department of Health Convergence, Seoul, Korea, Republic of (South)
    Greg Cook
    PhD,, Bristol Myers Squibb, Health Economics, Mulgrave, Australia
    Jonathan Karnon
    PhD, The University of Adelaide, School of Public Health, Adelaide, Australia
  • IP15 : CURRENT PRACTICES AND PROSPECTS IN MANAGING REIMBURSEMENT IN ASIA PACIFIC AND EUROPE: WHAT WE CAN DO MORE TO BRIDGE THE EXPERIENCE AND EXPECTATION?

    Presentation

    Adrian Griffin
    MSc, Johnson & Johnson, HTA & Reimbursement Policy, Buckinghamshire, United Kingdom
    Nathorn Chaiyakunapruk
    Pharm.D., Ph.D., Naresuan University, Center of Pharmaceutical Outcomes Research (CPOR), Department of Pharmacy Practice, Phitsanulok, Thailand
    Zhao Kun
    MD, PhD, MHSc, Division of Health Technology, Beijing, China
    Onozaki Kohei
    MS, Health and Global Policy Institute, Tokyo, Japan
  • IP16 : DOES TRANSPARENCY HELP OR HINDER EMERGING HTA SYSTEMS?

    Presentation

    Fiona Pearce
    MPH, Agency for Care Effectiveness, Ministry of Health, Singapore, Singapore, Singapore
    Wrik Ghosh
    BA, MSc, Costello Medical, Singapore, Singapore
    Thomas Butt
    PhD, Peking University, China Center for Health Economic Research, Beijing, China
    Brenda Pote
    MSc, Roche Singapore Pte. Ltd., Singapore, Singapore
  • IP17 : HOW COLLABORATIVE CAN COMPANIES BE IN DEVELOPING EVIDENCE TO SUPPORT MARKET ACCESS?

    Presentation

    Anthony Hatswell
    MSc, Delta Hat, Nottingham, United Kingdom
    Josie Godfrey
    BA, MA, MA, JG Zebra Consulting, London, United Kingdom
    Klair Bayley
    BSc, Save Our Sons Duchenne Foundation, Hurlstone Park, Australia
    David Pearce
    BPharm, MSc, Takeda Pharmaceuticals, Pricing Market Access and Health Economics, Singapore, Singapore
  • IP18 : HOW TO DEAL WITH MODEL UNCERTAINTY AT THE PLANNING STAGE OF COST-EFFECTIVENESS ANALYSIS?: TIPS FROM GLOBAL EXPERIENCES

    Presentation

    Presentation

    Presentation

    Joe Caputo
    BSc., Vista Health Pte Ltd., Singapore, Singapore
    Emiko Yoshida
    MSc., Healthcare to All, Tokyo, Japan
    George Papadopoulos
    BSc(Hons), GradDipEpi, Lucid Health Consulting Pty. Ltd., NSW, Australia
  • IP19 : OVERDIAGNOSIS AND ITS EXCESS COST FOR CANCER SCREENING

    Presentation

    Presentation

    Presentation

    Presentation

    Amy Ming-Fang Yen
    PhD, Taipei Medical University, Taipei, Taiwan
    Tony Hsiu-Hsi Chen
    PhD, National Taiwan University, Taipei, Taiwan
    Sherry Yueh-Hsia Chiu
    PhD, Chang Gung University, Taoyuan, Taiwan
    Chisato Hamashima
    MD, Teikyo University, Faculty of Medical Technology, Tokyo, Japan
  • IP2 : OPPORTUNITIES AND CHALLENGES IN INTERNATIONAL HARMONIZATION OF HTA OF MEDICAL DEVICES – GAPS BETWEEN EUROPEAN AND ASIAN COUNTRIES

    Presentation

    Presentation

    Presentation

    Sukyeong Kim
    PhD, RPh, MPH, National Evidence-Based Healthcare Collaborating Agency (NECA), Seoul, Korea, Republic of (South)
    Ataru Igarashi
    PhD, University of Tokyo, Department of Drug Policy and Management, Tokyo, Japan
    Rosanna Tarricone
    MSc, PhD, Bocconi University, SDA Bocconi School of Management, Milano, Italy
  • IP20 : DISCRETE CHOICE EXPERIMENTS AS A MEASURE OF SOCIAL VALUE AND PREFERENCES: APPLICATION TO POLICY MAKING IN ASIA-PACIFIC

    Presentation

    Presentation

    Presentation

    Stephen Goodall
    BSC, MSC, PhD, University of Technology Sydney, Centre for Health Economics Research and Evaluation, Sydney, Australia
    Ruoyan Gai
    PhD, National Center for Child Health and Development of Japan, Division of Policy Evaluation, Department of Health Policy and Chief, Division of Health Technology Assessment, Department of Clinical Epidemiology, Tokyo, Japan
    Brendan Mulhern
    MRes, University of Technology Sydney, Centre for Health Economics Research and Evaluation, Sydney, Australia
  • IP21 : DOES OVERSEAS EXPERIENCE OF MANAGED ENTRY AGREEMENTS INFORM THE NEW JAPANESE PRICING SCHEME FOR MEDICAL DEVICES?

    Presentation

    Presentation

    Presentation

    Kosuke Kato
    PhD, American Medical Devices and Diagnostics Manufacturers’ Association (AMDD), Nakano-ku, Japan
    Makoto Tamura
    PhD, International University of Health and Welfare, Ohtawara City, Japan
    Michael Drummond
    MCom, DPhil, University of York, Centre for Health Economics, York, United Kingdom
  • IP3 : HOW WILL PATIENT CENTRICITY BE CAPTURED IN THE JAPANESE HTA AND HEALTHCARE REFORM?

    Presentation

    Presentation

    Presentation

    Adrian Towse
    MA, MPhil, Office of Health Economics, London, United Kingdom
    Shunya Ikeda
    MD, International University of Health and Welfare, Narita city, Japan
    Durhane Wong-Rieger
    BA MA PHD, Canadian Organization for Rare Disorders, Toronto, Canada
  • IP4 : GLOBAL ALIGNMENT ON APPROACHES TO USE OF REAL WORLD EVIDENCE IN DECISION MAKING

    Presentation

    Nicholas Crabb
    PhD, NICE, Scientific Affairs, Manchester, United Kingdom
    David Pearce
    BPharm, MSc, Takeda Pharmaceuticals, Pricing Market Access and Health Economics, Singapore, Singapore
    Rob Thwaites
    MA, MCom, Takeda, London, United Kingdom
    Shunichi Fukuhara
    MD, PhD, Kyoto University, Kyoto, Japan
  • IP5 : BETTER THE DEVIL YOU KNOW? QALYs AND THEIR ALTERNATIVES IN DRUG REIMBURSEMENT DECISION-MAKING

    Presentation

    Presentation

    Presentation

    Danny Liew
    MBBS (Hons), BMedSc, FRACP, PhD, CertHealthEcon, Monash University, Melbourne, Australia
    J. Jaime Caro
    MDCM, McGill University, Medicine, Epidemiology, and Biostatistics, Montreal, Canada
    Mark Sculpher
    PhD, University of York, Centre for Health Economics, York, United Kingdom
  • IP6 : WHAT IS THE HTA IMPLICATION IN PATIENT ACCESS AND WHAT ARE THE CRITICAL FACTORS TO MAKE A BALANCE FOR INNOVATIVE MEDICINES? - 10 YEARS EXPERIENCES WITH HTA IN KOREA

    Presentation

    Presentation

    Eui-Kyung Lee
    PhD, School of Pharmacy, Sungkyunkwan University, Suwon, Korea, Republic of (South)
    Sungju Kim
    PhD, Novartis Korea, Patient Access, Seoul, Korea, Republic of (South)
  • IP7 : WHAT IS THE VALUE OF RARE DISEASE THERAPIES FOR DEVELOPING HEALTHCARE SYSTEMS?

    Presentation

    Ran Geng
    BSE, Venture Capital, Beijing, China
    Thomas Butt
    PhD, Peking University and University College London, China Center for Health Economic Research, Beijing, China
    Kevin Huang
    -, China Organization for Rare Disorders, Beijing, China
    Gordon G Liu
    PhD., National School of Development, Peking University, Beijing, China
  • IP8 : GLOBAL HORIZON SCANNING: POLICY IMPLICATIONS AND PRACTICALITIES

    Presentation

    Karen Facey
    PhD, University of Edinburgh, Usher Institute of Population Health Sciences and Informatics, Drymen, United Kingdom
    Kun Zhao
    MD, MHSci, China National Health Development Research Center, National Health and Family Planning Commission (NHFPC), China National Health Development Research Center, NHC, Beijing, China
    Sukyeong Kim
    PhD, RPh, MPH, National Evidence-based Health Care Collaborating Agency (NECA), Evidence-based Research Department, Seoul, Korea, Republic of (South)
    Franz Pichler
    PhD, Eli Lilly, Global Public Policy, Sydney, Australia

WORKSHOP PRESENTATIONS

  • W1 : HEALTH ECONOMIC EVALUATIONS TO SUPPORT PUBLIC HEALTH DECISION-MAKING IN VACCINES: ARE COST-EFFECTIVENESS ANALYSIS AND BUDGET IMPACT ANALYSIS SUFFICIENT TO ANSWER THE POLICY QUESTIONS?

    Presentation

    Presentation

    Sharon Zhang
    Ph D, GSK Vaccines, Singapore, Singapore
    Baudouin Standaert
    MD, PhD, GSK Vaccines, Wavre, Belgium
  • W13 : MODELLING DISEASE PROGRESSION AND ECONOMIC OUTCOMES OF DEMENTIA INTERVENTIONS: EXPLORING OPTIONS FOR A COMPLEX HEALTH PROBLEM

    Presentation

    Brendan Mulhern
    MRes, University of Technology Sydney, Centre for Health Economics Research and Evaluation, Sydney, Australia
    Tracy Comans
    PhD. B.Econ(Hons) B.Phty, University of Queensland, Centre for Health Services Research, Brisbane, Australia
    Jasmine Pwu
    PhD, MOHW, Taipei, Taiwan
    Kim-Huong Nguyen
    PhD, University of Queensland, Centre for Health Service Research, Brisbane, Australia
  • W14 : DELAYED ACCESS FOR PATIENTS WITH RARE DISEASES IN ASIA PACIFIC: FINDING A SOLUTION THAT WORKS

    Presentation

    Shanlian Hu
    MD, MSc, Shanghai Health Development Research Center, Shanghai, China
    Ming-Chin Yang
    Dr.PH, National Taiwan University, Public Health, Taipei, Taiwan
    Annabel Griffiths
    PhD, Costello Medical, Lawrenceville, United Kingdom
    Bertram Haeussler
    MD, IGES Institut GmbH, Berlin, Germany
  • W15 : DYNAMIC ADJUSTMENT MECHANISM FOR NATIONAL DRUG FORMULARY: INTERNATIONAL EXPERIENCES AND THE DEVELOPMENT IN CHINA

    Presentation

    Presentation

    Presentation

    Fei-Li Zhao
    PharmD, MS, PhD, University of Newcastle (UoN), Callaghan, Australia
    Jiuhong Wu
    PhD, PharmD, The 306th Hospital of PLA, Beijing, China
    Feng Xie
    BSc MSc PhD, McMaster University, Department of Health Research Methods, Evidence, and Impact (formerly Clinical Epidemiology and Biostatistics), Hamilton, Canada
  • W16 : THE APPLICATION OF INDICATION BASED PRICING TO REGENERATIVE MEDICINE THERAPIES: AN INTERACTIVE WORKSHOP

    Presentation

    Diana Brixner
    PhD, RPh, FAMCP, University of Utah, Executive Director, Pharmacotherapy Outcomes Research Center, and Director of Outcomes, Salt Lake City, USA
    Michael Drummond
    MCom, DPhil, University of York, Centre for Health Economics, Heslington, York, United Kingdom
    Masayuki Yamato
    PhD, Tokyo Women's Medical University, Institute of Advanced Biomedical Engineering and Science, Tokyo, Japan
    Mime Egami
    BA, University of Utah, Department of Pharmaceutics and Pharmaceutical Chemistry, Executive Director, Cell Sheet Tissue Engineering Regenerative Medicine Initiatives, Tokyo, Japan, Salt Lake City, USA
  • W17 : HOW E-CONNECTED MEDICINE WILL CHANGE THE VALUE OF PHARMACEUTICALS

    Presentation

    Presentation

    Presentation

    Presentation

    Taishiro Kishimoto
    MD, PhD, Keio University School of Medicine, Tokyo, Japan
    Ataru Igarashi
    PhD, University of Tokyo, Graduate School of Pharmaceutical Sciences, Department of Health Economics and Outcomes Research, Tokyo, Japan
    Yasuko Aitoku
    BS, Bayer Yakuhin Ltd., Osaka, Japan
    Mondher Toumi
    MD, PhD, MSc, Aix-Marseille University, Faculté de Médecine, Laboratoire de Santé Publique, Marseille, France
  • W18 : VALUE OF INFORMATION ANALYSIS: PRINCIPLES, APPLICATIONS AND GOOD PRACTICE RECOMMENDATIONS

    Presentations

    Lotte Steuten
    PhD, MSc, Fred Hutchinson Cancer Research Center, Seattle, USA
    Paul Scuffham
    PhD, Griffith University, Centre for Applied Health Economics, Brisbane, Australia
    Haitham Tuffaha
    BPharm, MBA, MSc, PhD, Griffith University, Centre for Applied Health Economics, Brisbane, Australia
  • W2 : THE EQ-5D-5L INSTRUMENT: PAST, PRESENT AND FUTURE

    Presentation

    Mark Oppe
    PhD, EuroQol Research Foundation, Rotterdam, Netherlands
    Nan Luo
    PhD, National University of Singapore, Saw Swee Hock School of Public Health, Singapore, Singapore
    Kim Rand
    PhD, University of Oslo, Department of Health Management and Health Economics, Oslo, Norway
  • W4 : THE NEW WAVE IN REAL WORLD EVIDENCE – INTEGRATED DATASETS

    Presentation

    Tom Haskell
    BS, Kantar Health, Global Operations, Horsham, USA
    Ataru Igarashi
    PhD, University of Tokyo, Graduate School of Pharmaceutical Sciences, Department of Health Economics and Outcomes Research, Tokyo, Japan
    Yuji Yamamoto
    M.D. MBA, MinaCare Co. Ltd., Tokyo, Japan
    Vince Grillo
    MBA, PhD, Kantar Health, Singapore, Singapore
  • W5 : JAPANESE HTA AND PRICING: CURRENT METHODS AND FUTURE POTENTIAL

    Presentation

    Presentation

    Isao Kamae
    MD, DrPH, The Univeristy of Tokyo, Graduate School of Public Policy, Tokyo, Japan
    Makoto Kobayashi
    PhD, M.Eng., CRECON Medical Assessment Inc., Tokyo, Japan
  • W6 : RESPONSE BASED COST-EFFECTIVENESS MODELING IN IMMUNO-ONCOLOGY

    Presentation

    Presentation

    Presentation

    Noemi Muszbek
    MSc, Evidera, London, United Kingdom
    Joe Zhuo
    PhD, Merck KGaA, Billerica, USA
    J. Jaime Caro
    MDCM, McGill University, Medicine, Epidemiology, and Biostatistics, Montreal, Canada
  • W7 : HOW CAN HTA METHODS BE ADAPTED TO MEET THE SPECIAL CHARACTERISTICS OF MEDICAL DEVICES?

    Presentation

    Presentation

    Presentation

    Michael Drummond
    MCom, DPhil, University of York, Centre for Health Economics, York, United Kingdom
    Rei Goto
    MD, PhD, Keio University, Graduate School of Business Administration, Yokohama, Japan
    Rosanna Tarricone
    MSc, PhD, Bocconi University, SDA Bocconi School of Management, Milano, Italy
  • W9 : BRIDGING THE GAP BETWEEN EFFICACY AND EFFECTIVENESS: USING BOTH REAL-WORLD AND TRIAL-BASED EVIDENCE TO IMPROVE CLINICAL DECISION MAKING

    Presentation

    Fei-Yuan Hsiao
    PhD, National Taiwan University, Graduate Institute of Clinical Pharmacy, Taipei, Taiwan
    Bor-Sheng Ko
    MD, PhD, National Taiwan University Hospital, BMT Unit and Hematology Division, Department of Internal Medicine, Taipei, Taiwan
    Ming-Hui Tai
    PhD, Amgen, Global Health Economics, Thousand Oaks, USA
    Han-I Wang
    PhD, University of York, Epidemiology & Cancer Statistics Group, York, United Kingdom

ISPOR FORUMS

  • F2 : HEALTH TECHNOLOGY ASSESSMENT OF MEDICAL DEVICES IN ASIA PACIFIC

    Presentation

    Presentation

    Presentation

    Presentation

    Presentation

    Devarshi Bhattacharyya
    MSc, MPH, Kalam Institute of Health Technology (KIHT), Visakhapatnam, India
    Richard J Milne
    BSc(Hons), MSc, PhD, University of Auckland, Health Outcomes Associates Ltd, and Associate Professor, School of Population Health, Auckland, New Zealand
    Alexandr Kostyuk
    MD, PhD, Ministry of Health and Social Development, Clinical Excellence at Republican Center for HealthCare Development and Chairman of the HTA Expert Group at Joint Committee for Quality Healthcare Services, Astana, Kazakhstan
    Wudong Guo
    PhD, National Health Commission, China National Health Development Research Center, Beijing, China
    Sukyeong Kim
    PhD, RPh, MPH, National Evidence-based Health Care Collaborating Agency (NECA), Evidence-based Research Department, Seoul, Korea, Republic of (South)
  • F3 : ISPOR SCIENTIFIC AND HEALTH POLICY GROUPS

    Presentation

    Clarissa Cooblall
    MPH, ISPOR, Scientific & Health Policy Initiatives, Lawrenceville, USA